RIVAROXABAN USE IN THE TREATMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM
https://doi.org/10.21518/2307-1109-2019-2-10-18
Abstract
This article contains information on the possibilities of using rivaroxaban and other non-vitamin K-associated oral anticoagulants (novel oral anticoagulant (NOAC)) in patients with pulmonary embolism (PE) in both acute and later stages of the disease. In 2019, the European Cardiology Society released updated clinical guidelines, which slightly changed the rules of treatment. The rules state that if the anticoagulant therapy is planned to be started with oral drugs, it is recommended to use one of NOACs. The results of the Einstein-PE randomized clinical study proved the efficacy and safety of rivaroxaban in acute pulmonary embolism. In this study, rivaroxaban showed efficacy for prevention cases of repeated pulmonary embolism that was noninferior to the standard therapy. On top of that, the use of rivaroxaban was associated with fewer large bleeding. The recommended regimen for the use of rivaroxaban in acute pulmonary embolism is 15 mg twice daily for 21 days, then 20 mg once daily for at least 3 months.
The article outlines issues related to the need to extend anticoagulant treatment beyond the established standard terms (3-6 months) and issues of choosing a drug for extended treatment. Among other NOACs, rivaroxaban has the most comprehensive evidence base for extended treatment after PE, as its efficacy has been proven in several studies. It is important to note that rivaroxaban is the only NOAC, which was superior not only to placebo (in the EINSTEIN-Extension study), but also to the active drug (more precisely, aspirin in the EINSTEIN-CHOICE study) in preventing the development of re-thromboembolism. At the same time, the safety profile of rivaroxaban was comparable with both placebo and aspirin.
The possibility to use NOACs in patients with active oncological disease is one of the new positions in modern clinical guidelines for the treatment of PE. As for rivaroxaban, the reason for this was the results of the SELECT-D study, in which rivaroxaban proved to be more efficient in preventing recurrence compared to the standard treatment with dalteparin, having comparable safety indicators in patients with cancer and PE.
Thus, the available data from several clinical studies in patients with PE (in the acute and long-term periods) confirm the possibility of active use of rivaroxaban in this clinical situation.
The article outlines issues related to the need to extend anticoagulant treatment beyond the established standard terms (3-6 months) and issues of choosing a drug for extended treatment. Among other NOACs, rivaroxaban has the most comprehensive evidence base for extended treatment after PE, as its efficacy has been proven in several studies. It is important to note that rivaroxaban is the only NOAC, which was superior not only to placebo (in the EINSTEIN-Extension study), but also to the active drug (more precisely, aspirin in the EINSTEIN-CHOICE study) in preventing the development of re-thromboembolism. At the same time, the safety profile of rivaroxaban was comparable with both placebo and aspirin.
The possibility to use NOACs in patients with active oncological disease is one of the new positions in modern clinical guidelines for the treatment of PE. As for rivaroxaban, the reason for this was the results of the SELECT-D study, in which rivaroxaban proved to be more efficient in preventing recurrence compared to the standard treatment with dalteparin, having comparable safety indicators in patients with cancer and PE.
Thus, the available data from several clinical studies in patients with PE (in the acute and long-term periods) confirm the possibility of active use of rivaroxaban in this clinical situation.
About the Author
A. D. Erlikh
State Budget Institution of Health of the city of Moscow «City Clinical Hospital No 29 them. NE Bauman Moscow Health Department»
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Head of Cardiovascular Resuscitation and Intensive Care Unit
2, Gospitalnaya ploshchad, Moscow, 123001, Russia
References
1. 2019 ESC Guidelines for the diagnosis and management of acute pulmonaryembolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2019;(00):1–61. doi: 10.1093/eurheartj/ehz405.
2. The EINSTEIN – PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med. 2012;(366):1287–1297. doi: 10.1056/NEJMoa1113572.
3. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Masiukiewicz U., Pak R., Thompson J., Raskob G.E., Weitz J.I. AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013;(369):799–808. doi: 10.1056/NEJMoa1302507.
4. The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med. 2013;(369):1406–1415. doi: 10.1056/NEJMoa1306638.
5. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., Baanstra D., Schnee J., Goldhaber S.Z. RE-COVER Study Group.Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi: 10.1056/NEJMoa0906598.
6. Schulman S., Kakkar A.K., Goldhaber S.Z., et al., on behalf of the RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72. doi: 10.1161/CIRCULATIONAHA.113.004450.
7. van Es N., Coppens M., Schulman S., Middeldorp S., Büller H.R. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;(124):1968–1975. doi: 10.1182/blood-2014-04–571232.
8. Romualdi E., Donadini M.P., Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011;9(7):841–844. doi: 10.1586/erc.11.62.
9. Weitz J.I., Lensing A.W.A., Prins M.H., Bauersachs R., Westendorf J.B., Bounameaux H., Brighton T.A., Cohen A.T., Davidson B.L., Decousus H., Freitas M.C.S., Holberg G. et al. for the EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;(376):1211–1222. doi: 10.1056/NEJMoa1700518.
10. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Porcari A., Raskob G.E., Weitz J.I. AMPLIFY-EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013;368(8):699–708. doi: 10.1056/NEJMoa1207541.
11. Simes J., Becattini C., Agnelli G., Eikelboom J.W., Kirby A.C., Mister R., Prandoni P., Brighton T.A. INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062–1071. doi: 10.1161/CIRCULATIONAHA.114.008828.
12. Young A.M., Marshall A., Thirlwall J., Chapman O., Lokare A., Hill C., Hale D., Dunn J.A., Lyman G.H., Hutchinson C., MacCallum P., Kakkar A., Hobbs F.D.R., Petrou S., Dale J., Poole C.J., Maraveyas A., Levine M. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi: 10.1200/JCO.2018.78.8034.
Review
For citations:
Erlikh A.D. RIVAROXABAN USE IN THE TREATMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM. Aterotromboz = Atherothrombosis. 2019;(2):10-18. (In Russ.) https://doi.org/10.21518/2307-1109-2019-2-10-18
Views:
2758
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 